Skip to content
Canine PeptideResearch peptides

Peptides for Dachshund osteoarthritis

The short answer

Dachshunds carry an elevated predisposition to osteoarthritis. The compounds investigated for it are BPC-157, TB-500, GHK-Cu. At a typical Dachshund weight of 4–15 kg (9–33 lb), this breed falls in the small / toy breed dosing class.

Osteoarthritis in Dachshunds

Osteoarthritis is the endpoint of many different joint problems: dysplasia, old injuries, cruciate disease, or simply years of loading. Cartilage thins, the joint capsule inflames, bone remodels at the margins, and the dog compensates by moving less — which accelerates the muscle loss that makes the joint less stable still. Research interest in peptides here centres on interrupting that cycle: reducing inflammatory signalling, supporting soft tissue around the joint, and improving comfort enough that the dog moves normally again.

Dosing at Dachshund body weight

Calculated for a 10 kg (22 lb) dog — the midpoint of the typical range for this breed.

CompoundDose at 10 kgFrequencyEvidence
BPC-15720–100 mcgOnce dailyEmerging evidence
TB-5001–2.5 mgLoading 1-2x weekly, then half dose weeklyEmerging evidence
GHK-Cu0.5-1 mg per day injectable, or topical twice dailyDaily (injectable) / twice daily (topical)Emerging evidence

Weigh your dog rather than using a breed average — an individual Dachshund can sit well outside the typical range. Use the dose calculator for an exact figure.

Common questions

What peptides are used for osteoarthritis in Dachshunds?+

BPC-157, TB-500, GHK-Cu are investigated for osteoarthritis. No breed-specific pharmacological restriction is established for Dachshunds among these compounds.

How much should a Dachshund be given?+

Dachshunds typically weigh 4–15 kg (9–33 lb), placing them in the small / toy breed class. BPC-157: approximately 20–100 mcg at 10 kg. TB-500: approximately 1–2.5 mg at 10 kg. Weigh your dog rather than relying on a breed average.

Are Dachshunds more prone to osteoarthritis?+

Yes. Dachshunds carry an elevated predisposition to osteoarthritis. Progressive cartilage loss and joint inflammation, affecting a large share of dogs over eight years old.

References

  1. 1.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
  2. 2.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
  3. 3.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
  4. 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
  5. 5.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
  6. 6.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
  7. 7.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
  8. 8.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
  9. 9.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
  10. 10.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
  11. 11.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
  12. 12.Canapp SO Jr, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 2003. PMID 14648529
  13. 13.Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID 8227353
  14. 14.Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMID 26236730
  15. 15.Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018. PMID 29986520

Other conditions Dachshunds are predisposed to: Intervertebral disc disease (IVDD).

Where to source research peptides

Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.

Visit Pet & Peps Research →How to evaluate a supplier

Educational information — not veterinary medical advice

Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.